CommercialPrior AuthMedium impact
Teduglutide (Gattex) (CPB 0849, reviewed 2026-06-10)
Aetna·Gastroenterology, Pediatrics, General Surgery·Medical Policy
We identified it
Aug 17, 2026
Summary
Aetna has issued a fresh clinical policy (CPB 0849, reviewed 2026-06-10) establishing coverage criteria for teduglutide (Gattex) in short bowel syndrome. The policy requires precertification for all commercial plans, restricts prescribing to gastroenterologists or SBS specialists, and defines specific approval criteria based on parenteral nutrition dependence duration and reduction thresholds. Coverage is limited to SBS; all other indications are experimental/investigational.
Action Required
Immediately: (1) Billing team must implement mandatory precertification requirement for teduglutide (Gattex) claims before submission to Aetna. (2) Update billing system to flag all Gattex claims for precertification via phone (866) 752-7021 or fax (888) 267-3277. (3) Providers must verify prescriber is a gastroenterologist or SBS specialist before processing claims; reject non-qualifying prescribers. (4) Implement validation logic in billing software: Initial approval requires adult patients on parenteral nutrition/IV fluids ≥3x/week for ≥12 months, OR pediatric patients <18 years with PN/IV fluids ≥30% of caloric/fluid needs. (5) For continuation therapy, confirm either ≥20% reduction in parenteral support from baseline OR complete weaning from parenteral support while on therapy. (6) Deny or request prior auth for all non-SBS diagnoses (Crohn's disease, GVHD, radiation enteritis, diabetes, GIST, etc.) per experimental/investigational list. (7) Providers must obtain Statement of Medical Necessity (SMN) via Specialty Pharmacy Precertification process. Failure to obtain precertification will result in claim denials.